44
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In this case report, we presented a case of myocarditis as a rare complication that developed after Covid mRNA‐1273 vaccine. Cases of post‐vaccine myocarditis usually progress with mild symptoms. However, it should be a situation that healthcare workers should keep in mind, that myocarditis may develop after vaccination.

          Abstract

          Although cases of post‐vaccine myocarditis usually progress with mild symptoms and do not cause any serious complications, post‐vaccine myocarditis should be a condition that healthcare professionals should keep in mind.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          mRNA vaccines — a new era in vaccinology

          mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

            In this position statement of the ESC Working Group on Myocardial and Pericardial Diseases an expert consensus group reviews the current knowledge on clinical presentation, diagnosis and treatment of myocarditis, and proposes new diagnostic criteria for clinically suspected myocarditis and its distinct biopsy-proven pathogenetic forms. The aims are to bridge the gap between clinical and tissue-based diagnosis, to improve management and provide a common reference point for future registries and multicentre randomised controlled trials of aetiology-driven treatment in inflammatory heart muscle disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management

              Human coronavirus-associated myocarditis is known, and a number of COVID-19-related myocarditis cases have been reported. The pathophysiology of COVID-19-related myocarditis is thought to be a combination of direct viral injury and cardiac damage due to the host’s immune response. COVID-19 myocarditis diagnosis should be guided by insights from previous coronavirus and other myocarditis experience. The clinical findings include changes in ECG, cardiac biomarkers, and impaired cardiac function. When cardiac MRI is infeasible, cardiac CT angiography with delayed myocardial imaging may serve to exclude significant coronary artery disease and identify myocardial inflammatory patterns. Because many COVID-19 patients have cardiovascular comorbidities, myocardial infarction should be considered. Where the diagnosis remains uncertain, an endomyocardial biopsy may help identify active cardiac infection through viral genome amplification and possibly refine the treatment risks of systemic immunosuppression. Arrhythmias are not uncommon in the COVID-19 patients; however, its pathophysiology is still speculative. Nevertheless, clinicians should be vigilant to provide prompt monitoring and treatments. The long-term impact of COVID-19 myocarditis, including in the majority of mild cases remains unknown.
                Bookmark

                Author and article information

                Contributors
                drsuhaturkmen@hotmail.com
                Journal
                Clin Case Rep
                Clin Case Rep
                10.1002/(ISSN)2050-0904
                CCR3
                Clinical Case Reports
                John Wiley and Sons Inc. (Hoboken )
                2050-0904
                18 April 2022
                April 2022
                : 10
                : 4 ( doiID: 10.1002/ccr3.v10.4 )
                : e05741
                Affiliations
                [ 1 ] Department of Emergency Medicine Hamad Medical Corporation Doha Qatar
                [ 2 ] Department of Emergency Medicine Acibadem University Istanbul Turkey
                [ 3 ] ringgold 36977; Department of Cardiology Medicine Hamad Medical Corporation Doha Qatar
                [ 4 ] ringgold 36977; Department of Radiology Hamad Medical Corporation Doha Qatar
                Author notes
                [*] [* ] Correspondence

                Süha Türkmen, Department of Emergency Medicine, Hamad Medical Corporation, Doha, Qatar.

                Email: drsuhaturkmen@ 123456hotmail.com

                Author information
                https://orcid.org/0000-0002-0557-6071
                Article
                CCR35741
                10.1002/ccr3.5741
                9014704
                35449778
                2a794faf-56db-4dd4-96fe-83e861fd8845
                © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 24 February 2022
                : 08 August 2021
                : 28 March 2022
                Page count
                Figures: 5, Tables: 0, Pages: 4, Words: 1935
                Funding
                Funded by: Qatar National Library
                Funded by: Hamad Medical Corporation , doi 10.13039/100007833;
                Categories
                Case Report
                Case Reports
                Custom metadata
                2.0
                April 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.4 mode:remove_FC converted:18.04.2022

                covid‐19,mrna‐1273 vaccine,myocarditis
                covid‐19, mrna‐1273 vaccine, myocarditis

                Comments

                Comment on this article